EDITORIAL article
Front. Immunol.
Sec. Parasite Immunology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1666020
This article is part of the Research TopicLeishmaniasis and Immunity: Challenges, Advances and Future PerspectiveView all 9 articles
Editorial: Leishmaniasis and Immunity: Challenges, Advances and Future Perspective
Provisionally accepted
- 1Fischell Department of Bioengineering, A. James Clark School of Engineering, University of Maryland, College Park, College Park, United States
- 2The Ohio State University, Columbus, United States
- 3University of Texas MD Anderson Cancer Center Houston, United States, Houston, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Editorial on the Research Topic: Leishmaniasis and Immunity: Challenges, Advances and Future Perspective Leishmaniasis is still one of the most prevalent parasitic diseases in tropical and subtropical regions of the world [1]. Despite sustained global efforts and collaborative initiatives over the past two decades, cutaneous leishmaniasis (CL) continues to account for hundreds of thousands of new cases annually [2]. Meanwhile, visceral leishmaniasis (VL) persists as the second most fatal disease among parasitic diseases after malaria in these regions.Although over a century has passed since the discovery of pentavalent antimonials, the emergence of drug resistance in several endemic areas has significantly reduced its efficacy [3]. Currently, most therapeutic options in use or under clinical evaluation for leishmaniasis are repurposed drugs, underscoring the need for new treatment strategies. Molecular tools have considerably improved the detection of Leishmania species and identification of asymptomatic infections, facilitated by point-of-care diagnostics in resource-limited field settings. However, the development of an effective and accessible vaccine remains elusive [4].The biology of Leishmania infection is inherently complex, with different species causing distinct clinical manifestations influenced by multiple factors, most notably host-parasite interactions, which ultimately determine disease outcome [5]. To survive within the hostile environment of host macrophages, the parasite has evolved various immune evasion strategies [6]. Therefore, a deeper understanding of the dynamic interplay between parasite virulence mechanisms and host immune defenses, particularly in an epigenetic framework,
Keywords: Leishmaniasis, Host-Parasite Interactions, immune response, Parasite survival, Visceral leishmaniasis, cutaneous leishmaniasis
Received: 15 Jul 2025; Accepted: 24 Jul 2025.
Copyright: © 2025 Ejazi, Satoskar and Singh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Sarfaraz Ahmad Ejazi, Fischell Department of Bioengineering, A. James Clark School of Engineering, University of Maryland, College Park, College Park, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.